We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Thomas
Brown
thomas.brown@porthosp.nhs.uk
Laura
Wiffen
Laura.wiffen@porthosp.nhs.uk
Chronic lower respiratory diseases
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Currently,there is no single test to diagnose asthma; instead,it’s based on a combination of clinical history,different
investigations,and ‘trial by treatment’,leading to diagnostic uncertainty and over- or under-treatment. We want to try
and make the journey to a diagnosis of asthma easier and quicker,and through this study we hope to test new
devices that could be used in both GP practices and hospitals to help make the diagnosis of asthma. This trial aims to
evaluate novel diagnostic technologies for asthma in 3 different pathways providing the necessary evidence-base to
allow adoption into clinical practice:
• Pathway 1 evaluates whether the technology can distinguish between people with asthma and healthy volunteers,and other respiratory conditions in a well characterised secondary-care population and whether the parameters they
measure correlate with the current standard diagnostic tests;
• Pathway 2 assesses whether the technology can accurately diagnose asthma (either independently or alongside
current diagnostic tests) in a primary care population of patients where there is a clinical suspicion of asthma;
• Pathway 3 explores the ability of the technology to identify clinically important phenotypic characteristics which are
difficult to measure in primary care and/or significantly impact on patient management and treatment
The novel technology and devices will be entered into the pathway most suited to their stage of development,with this
study design also allowing information collected for participants with a confirmed diagnosis of asthma in pathways 1
or 2 to be included in pathway 3. Participants will undergo the investigations currently used to diagnose asthma as
well as using the novel devices being investigated in the relevant pathway (currently N-tidal and Inflammacheck).
These devices have been used in earlier studies and measure different physical,biological and chemical changes in
breath which have been shown to be different in people with asthma.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Device;
You can take part if:
You may not be able to take part if:
Pathway 1: For all groups other than Healthy Volunteers: • Known clinically significant chest wall,neuromuscular,cardiac or other co-morbidity or abnormality that would affect spirometry and/or other measures of lung function/inflammation (in the opinion of the investigator) • Respiratory tract infection/exacerbation of respiratory condition requiring systemic corticosteroids and/or antibiotic treatment within the last 2 weeks • Current smokers or Ex-smokers with >20 PYH (other than COPD and asthma with significant smoking history group) • The participant is unable to provide informed consent or is unable to complete the study procedures Pathway 2: • A low clinical probability of asthma (as defined within the NICE diagnostic algorithm) • The participant is unable to provide informed consent or is unable to complete the study procedures • Respiratory tract infection/exacerbation of respiratory condition requiring systemic corticosteroids and/or antibiotic treatment within the last 2 weeks • Hospital admission in the last 4 weeks for a respiratory condition
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by PORTSMOUTH HOSPITALS UNIVERSITY NATIONAL HEALTH SERVICE TRUST and funded by ASTHMA UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 54677
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
